Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03056534 · ClinicalTrials.gov registry record

R3 Delta Ceramic Acetabular System PAS U.S.

A clinical trial of Degenerative Joint Disease, sponsored by Smith & Nephew.

Completed
Registry status
189
Enrollment target
8
Study locations

NCT03056534 is a study of Degenerative Joint Disease that has completed, run by Smith & Nephew. The registered enrollment target is 189 participants, below the 395-participant average among 4 other Degenerative Joint Disease trials with a reported enrollment target (52% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03056534, a study of Degenerative Joint Disease, has completed, sponsored by Smith & Nephew.

COMPLETED
Registry status
189 participants
Enrollment target
8
Study locations

Study Summary

R3 Delta Post-Approval Study U.S.

Conditions Studied

Interventions

  • DEVICE R3 Biolox Delta Ceramic Acetabular System

Study Locations (8)

Maryland

  • Luminis Health - Annapolis
  • Rubin Institute for Advanced Orthopedics, Sinai Hospital - Baltimore

Texas

  • St. David's Center for Hip and Knee Replacement - Austin
  • INOV8 Healthcare - Houston

Florida

  • Foundation for Orthopaedic Research and Education - Tampa

Georgia

  • Emory University - Tucker

Nevada

  • Reno Orthopaedic Clinic Foundation - Reno

Pennsylvania

  • University of Pennsylvania, Department of Orthopaedic Surgery - Philadelphia

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2018-02-07
Est. Completion 2023-05-31

Sponsor

Smith & Nephew

72 total trials

What the Registry Record Tells You About NCT03056534

The ClinicalTrials.gov registry entry for NCT03056534 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 395-participant average among 4 other Degenerative Joint Disease trials with a reported enrollment target (52% lower). The listed sponsor is Smith & Nephew, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Degenerative Joint Disease appearing as the primary indexed condition, and to 1 intervention - of which R3 Biolox Delta Ceramic Acetabular System is the first listed.

NCT03056534 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Maryland, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT03056534 about?

NCT03056534 is a clinical study titled "R3 Delta Ceramic Acetabular System PAS U.S.". R3 Delta Post-Approval Study U.S.

What is the current status of trial NCT03056534?

This trial is currently completed. The enrollment target is 189 participants. The study started on 2018-02-07. Estimated completion is 2023-05-31.

What conditions does trial NCT03056534 study?

This clinical trial studies the following conditions: Degenerative Joint Disease.

What interventions are being tested in trial NCT03056534?

The interventions under investigation include: R3 Biolox Delta Ceramic Acetabular System (DEVICE).

Who is sponsoring clinical trial NCT03056534?

This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03056534 being conducted?

This trial has 8 study locations across Florida, Georgia, Maryland, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Degenerative Joint Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.